--- title: "Minerva Neurosciences (NERV.US) — 財務報表" type: "Symbol" locale: "zh-HK" url: "https://longbridge.com/zh-HK/quote/NERV.US/norm.md" symbol: "NERV.US" name: "Minerva Neurosciences" parent: "https://longbridge.com/zh-HK/quote/NERV.US.md" datetime: "2026-03-12T23:01:18.718Z" locales: - [en](https://longbridge.com/en/quote/NERV.US/norm.md) - [zh-CN](https://longbridge.com/zh-CN/quote/NERV.US/norm.md) - [zh-HK](https://longbridge.com/zh-HK/quote/NERV.US/norm.md) --- > 支持的語言: [English](https://longbridge.com/en/quote/NERV.US/norm.md) | [简体中文](https://longbridge.com/zh-CN/quote/NERV.US/norm.md) # Minerva Neurosciences (NERV.US) — 財務報表 ## 損益表 (USD) | 指標 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | | --- | --- | --- | --- | --- | --- | | EPS | -25.51 | -0.3625 | -0.4305 | -0.4958 | -0.5644 | | ROE | 1294.34% | 32.92% | 42.56% | 54.75% | 72.16% | | Revenue | - | - | - | - | - | | Net income | -283.67M | -2.74M | -3.26M | -3.75M | -4.27M | | Operating income | -4.98M | -2.84M | -3.37M | -3.90M | -4.52M | | Gross margin | - | - | - | - | - | | Net margin | - | - | - | - | - | | Profit quality | - | - | - | - | - | ## 資產負債表 (USD) | 指標 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | | --- | --- | --- | --- | --- | --- | | A&L | 97.97M | 28.09M | 30.42M | 32.80M | 37.14M | | Leverage | -0.7215 | -0.8124 | -0.9474 | -1.13 | -1.45 | | BVPS | -12.66 | -4.94 | -4.59 | -4.17 | -3.67 | | Turnover | - | - | - | - | - | | Cash & STI | 82.30M | 12.29M | 15.25M | 17.29M | 21.36M | | Inv & Rec | - | - | - | - | - | | LT assets | - | 1360.00 | 2721.00 | 4081.00 | 5442.00 | | Net debt | -22.30M | 47.71M | 44.75M | 42.71M | 38.64M | ## 現金流量表 (USD) | 指標 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | | --- | --- | --- | --- | --- | --- | | Operating CF | - | -2.92M | -2.04M | -4.07M | -5.17M | | Investing CF | - | - | - | - | - | | Financing CF | - | -45166.00 | - | - | - | | Free CF | - | -1.79M | -892393.00 | -2.76M | -3.72M | | OCF coverage | - | - | - | - | - | | Repaid & issued | - | - | - | - | - | | CapEx | - | - | - | - | - |